Susan Tousi, Illumina’s chief commercial officer, is slated to leave the company in the latest executive shakeup after a CEO change last year.
Named chief commercial officer in 2021, Tousi has led the company’s product development since 2012. Under her leadership, Illumina has released a portfolio of DNA sequencers that made it the largest company of its kind, though the company’s growth has stalled and rival products have slowly gained traction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.